Zai Lab Receives Orphan Drug Status for ADC for Neuroendocrine Carcinomas

The US FDA has granted Orphan Drug status to Zai Lab's (LAB) antibody-drug conjugate zocilurtatug pelitecan for neuroendocrine carcinomas. - The asset previously received Fast Track designation for other indications, including small cell lung cancer. - Zoci targets Delta-like...<

The US FDA has granted Orphan Drug status to Zai Lab’s (LAB) antibody-drug conjugate zocilurtatug pelitecan for neuroendocrine carcinomas. – The asset previously received Fast Track designation for other indications, including small cell lung cancer. – Zoci targets Delta-like…

gand 3 (DLL3), which is overexpressed in many neuroendocrine carcinomas

Leave a Reply

Your email address will not be published. Required fields are marked *